Cargando…

Population Pharmacokinetics of Revefenacin in Patients with Chronic Obstructive Pulmonary Disease

BACKGROUND AND OBJECTIVES: Revefenacin is a lung-selective, long-acting muscarinic antagonist indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease. The objectives of this analysis were to evaluate the pharmacokinetics of revefenacin and its major metabolite...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lo, Arthur, Borin, Marie T., Bourdet, David L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932972/ https://www.ncbi.nlm.nih.gov/pubmed/33124005 http://dx.doi.org/10.1007/s40262-020-00938-3

Ejemplares similares

Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
por: Borin, Marie T, et al.
Publicado: (2019)

The Role of Revefenacin in Chronic Obstructive Pulmonary Disease
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

The Efficacy and Safety of Revefenacin for the Treatment of Chronic Obstructive Pulmonary Disease: A Systematic Review
por: Zhang, Jiaxing, et al.
Publicado: (2021)

Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease
por: Donohue, James, et al.
Publicado: (2019)

Revefenacin, a Long‐Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo‐ and Positive‐Controlled Thorough QT Study
por: Borin, Marie T., et al.
Publicado: (2019)

Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease
por: Hvisdas, Christopher
Publicado: (2021)

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)
por: Donohue, James F., et al.
Publicado: (2019)

Revefenacin: First Global Approval
por: Heo, Young-A
Publicado: (2018)

A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease
por: Pudi, Krishna K., et al.
Publicado: (2017)

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials
por: Sethi, Sanjay, et al.
Publicado: (2020)

Correction to: Revefenacin: First Global Approval
por: Heo, Young-A
Publicado: (2019)

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
por: Mehta, Rashmi, et al.
Publicado: (2019)

Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease
por: Siederer, Sarah, et al.
Publicado: (2015)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

Pharmacokinetics of Ampreloxetine, a Norepinephrine Reuptake Inhibitor, in Healthy Subjects and Adults with Attention-Deficit/Hyperactive Disorder or Fibromyalgia Pain
por: Kanodia, Jitendra, et al.
Publicado: (2020)

Population Pharmacokinetics and Dose Optimization of Ceftazidime and Imipenem in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease
por: Nguyen, Thu-Minh, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension
por: Lo, Arthur, et al.
Publicado: (2021)

Tigecycline Pharmacokinetic and Pharmacodynamic Profile in Patients with Chronic Obstructive Pulmonary Disease Exacerbation
por: Kipourou, Maria, et al.
Publicado: (2023)

Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID‐19
por: Pfeifer, Nathan D., et al.
Publicado: (2021)

Safety, Pharmacokinetics, and Pharmacodynamics of TD‐0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects
por: Kanodia, Jitendra, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease
por: Hohlfeld, JM, et al.
Publicado: (2014)

Chronic Obstructive Pulmonary Disease in the LGBTQI+ Population
por: Sirufo, Maria Maddalena, et al.
Publicado: (2022)

Over diagnosis of chronic obstructive pulmonary disease in an underserved patient population
por: Ghattas, Christian, et al.
Publicado: (2013)

Correlation of chronic obstructive pulmonary disease assessment test and clinical chronic obstructive pulmonary disease questionnaire score with BODE index in patients of stable chronic obstructive pulmonary disease
por: Singh, Shashank, et al.
Publicado: (2018)

Impact of obstructive sleep apnea on pulmonary hypertension in patients with chronic obstructive pulmonary disease
por: Sun, Wan-Lu, et al.
Publicado: (2019)

Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease
por: Facius, Axel, et al.
Publicado: (2018)

Outpatient pulmonary rehabilitation in patients with chronic obstructive pulmonary disease
por: Barakat, Shahin, et al.
Publicado: (2008)

Association of metabolic syndrome with chronic obstructive pulmonary disease in an Indian population
por: Acharyya, Amitava, et al.
Publicado: (2016)

Chronic Obstructive Pulmonary Disease with Anemia as Comorbidity in North Indian Population
por: Pandey, Sarika, et al.
Publicado: (2018)

Reply: Chronic Obstructive Pulmonary Disease in the LGBTQI+ Population
por: Krishnan, Jamuna K., et al.
Publicado: (2022)

Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease
por: Tutar, Nuri, et al.
Publicado: (2013)

Serum Procalcitonin Levels in Chronic Obstructive Pulmonary Disease Patients in North Indian Population
por: Pandey, Sarika, et al.
Publicado: (2019)

Prevalence of pulmonary artery hypertension in patients of chronic obstructive pulmonary disease and its correlation with stages of chronic obstructive pulmonary disease, exercising capacity, and quality of life
por: Gupta, Kamlesh Kumar, et al.
Publicado: (2018)

Association of Metabolic Syndrome with the Severity of Airflow Obstruction in Patients with Chronic Obstructive Pulmonary Disease
por: Bermudez, Gherald, et al.
Publicado: (2018)

Exacerbation of Chronic Obstructive Pulmonary Disease
por: Zhou, Xianghui, et al.
Publicado: (2015)

Association of sarcopenia with osteoporosis in patients with chronic obstructive pulmonary disease
por: Chua, Jamie R., et al.
Publicado: (2020)

Human metapneumovirus and exacerbations of chronic obstructive pulmonary disease()
por: Martinello, Richard A., et al.
Publicado: (2006)

Cancer risk in patients with chronic obstructive pulmonary disease
por: Schneider, Cornelia, et al.
Publicado: (2010)

Quadriceps strength in patients with chronic obstructive pulmonary disease
por: Shah, Swati, et al.
Publicado: (2019)

Aspergillus colonization in patients with chronic obstructive pulmonary disease
por: Shahi, M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qb85obr71lv0h2k3pdovg8vjkn